<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2299">
  <stage>Registered</stage>
  <submitdate>23/03/2009</submitdate>
  <approvaldate>23/03/2009</approvaldate>
  <nctid>NCT00867880</nctid>
  <trial_identification>
    <studytitle>Pharmacokinetic Study Of Ibuprofen Injection (IVIb) In Healthy Adult Subjects</studytitle>
    <scientifictitle>A Randomized, Double-Blind, Placebo-Controlled, Single Dose, Crossover Study of the Pharmacokinetics, Safety and Tolerability of Ibuprofen Inejction (IVIb) In Healthy Adult Volunteers</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CPI-CL-011</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Healthy</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - IVIb

Experimental: 1 - 

Active Comparator: 2 - 


Treatment: drugs: IVIb
800mg IVIb diluted in 200mL NS will be given IV (in the vein) concurrently with an oral placebo on Day 1 and 200ml Normal Saline will be given IV (in the vein)concurrently with 800mg oral ibuprofen on Day 8

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To evaluate the pharmacokinetic profile of a single dose of IVIb administered over 5-7 minutes.</outcome>
      <timepoint>12 hours</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To evaluate the safety and tolerability of a single dose of IVIb in healthy adult participants.</outcome>
      <timepoint>12 hours</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Healthy volunteers between the ages of 18 and 65 years (at the time of consent).</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Participants lacking good venous access in both arms.

          -  History of allergy or hypersensitivity to NSAIDs or any component of intravenous
             ibuprofen.

          -  Have never taken aspirin or ibuprofen

          -  History of abuse of alcohol or other drugs in the 2 months before CTM administration.

          -  Have used prescription drugs (not including oral contraceptives) within 14 days before
             CTM administration or have used aspirin within one week before CTM administration or
             over-the-counter pain relievers (NSAIDs or acetaminophen) within 3 days before CTM
             administration.

          -  Have taken investigational drugs within 30 days before CTM administration.

          -  Have donated blood or blood products within 30 days before CTM administration.

          -  Be pregnant or nursing.

          -  Have had breast cancer.

          -  Have a clinically significant laboratory test

          -  Presence or history of the following conditions: asthma, bleeding tendency,
             hypertension, heart failure, peptic ulcer disease, inflammatory bowel disease, or any
             other gastrointestinal disorder, renal or hepatic disease..

          -  Have a calculated creatinine clearance (estimated by means of the Cockcroft-Gault
             equation) of &lt; 75mL/min

          -  Inability to understand the requirements of the study. Participants must be willing to
             provide written informed consent (as evidenced by signature on an informed consent
             document approved by an Institutional Review Board [IRB]), and agree to abide by the
             study restrictions.

          -  Refusal to provide written authorization for use and disclosure of protected health
             information

          -  Be otherwise unsuitable for the study, in the opinion of the Investigator.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>12</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/06/2009</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
    <hospital>Centre for Pharmaceutical Research - Underdale</hospital>
    <postcode>5032 - Underdale</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Cumberland Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary objective of this study is to evaluate the pharmacokinetic profile of a single
      dose of IVIb administered over 5-7 minutes.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00867880</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Robert Milne, Associate Professor</name>
      <address>Centre for Pharmaceutical Research</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>